Minaris Regenerative Medicine, LLC
15 articles about Minaris Regenerative Medicine, LLC
-
Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications
5/24/2023
Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations.
-
Biopharma companies from around the globe provide updates on their businesses and pipelines.
-
BioSpace Global Roundup, May 14
5/14/2020
Biopharma and life sciences companies from across the globe provide updates on their pipeline and business. -
Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio
5/11/2020
Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH, both subsidiaries of Hitachi Chemical Co., Ltd. announced that they have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:.
-
Hitachi Chemical Co. Ltd. to Acquire apceth Biopharma GmbH, Expanding Global Footprint of its Cell and Gene Therapy Contract Development and Manufacturing Services
1/31/2019
apceth Biopharma manufactures cell and gene therapy products for American and European clients through two manufacturing sites in Munich, Germany, certified for GMP manufacture since 2010
-
Hitachi Chemical Advanced Therapeutics Solutions Signs Three-Year Agreement with GSK to Provide Clinical Manufacturing for T Cell Therapy
10/1/2018
HCATS will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials.
-
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product SB623 with Hitachi Chemical
3/13/2018
SanBio Group and Hitachi Chemical Co., Ltd. jointly announced that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC, they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio.
-
Hitachi Chemical Co., Ltd. Completes Acquisition Of PCT, Expanding Cell Therapy Outsourcing Business
5/19/2017
-
Caladrius Biosciences Closes The Sale Of Its Remaining Interest In PCT To Hitachi Chemical Co., Ltd. For $75 Million
5/19/2017
-
Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million
3/17/2017
-
Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million
3/17/2017
-
Hitachi Chemical Co., Ltd. Developed Novel Molecular Testing System for Personalized Medicine – Novel mRNA Quantitative Assay for Biomarker Discovery and Prediction of Drug Efficacy
11/15/2012
-
A*STAR's Institute of Microelectronics and Hitachi Chemical Co., Ltd. to Develop 3D IC Packaging Material Technologies
9/13/2012
-
Basic Patents Granted for Hitachi Chemical Co., Ltd.'s Fluid Circuit Sheet ''microARTs''
9/6/2007
-
Response Genetics, Inc. Signs Collaboration Agreement With Hitachi Chemical Co., Ltd. to Provide Diagnostic Testing Services to Asia-Pacific
7/30/2007